NCT03417739View on ClinicalTrials.gov

A Phase II Study of BVD-523 in Metastatic Uveal Melanoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

March 26, 2018

Primary Completion Date

May 5, 2020

Study Completion Date

August 31, 2025

Conditions
Uveal Melanoma
Interventions
DRUG

BVD-523

ERK1 and ERK2 inhibitor

Trial Locations (2)

02214

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

BioMed Valley Discoveries, Inc

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER

NCT03417739 - A Phase II Study of BVD-523 in Metastatic Uveal Melanoma | Biotech Hunter | Biotech Hunter